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Foreword
As the largest organ of the body, the skin performs multiple critical functions, such as 
serving as the primary barrier to the external environment. For this reason, the skin is 
often exposed to potentially hazardous agents, including chemicals, which may contribute 
to the onset of a spectrum of adverse health effects ranging from localized damage (e.g., 
irritant contact dermatitis and corrosion) to induction of immune-mediated responses 
(e.g., allergic contact dermatitis and pulmonary responses), or systemic toxicity (e.g., 
neurotoxicity and hepatoxicity). Understanding the hazards related to skin contact with 
chemicals is a critical component of modern occupational safety and health programs.
In 2009, the National Institute for Occupational Safety and Health (NIOSH) published 
Current Intelligence Bulletin (CIB) 61: A Strategy for Assigning New NIOSH Skin Nota-
tions [NIOSH 2009–147]. This document provides the scientific rationale and frame-
work for the assignment of multiple hazard-specific skin notations (SK) that clearly 
distinguish between the systemic effects, direct (localized) effects, and immune-mediated 
responses caused by skin contact with chemicals. The key step within assignment of the 
hazard-specific SK is the determination of a substance’s hazard potential, or its poten-
tial for causing adverse health effects as a result of skin exposure. This determination 
entails a health hazard identification process that involves use of the following:
 • Scientific data on the physicochemical properties of a chemical
 • Data on human exposures and health effects
 • Empirical data from in vivo and in vitro laboratory testing
 • Computational techniques, including predictive algorithms and mathematical 
models that describe a selected process (e.g., skin permeation) by means of ana-
lytical or numerical methods. 
This Skin Notation Prof ile provides the SK assignment and supportive data for 
1,3-dichloropropene (1,3-D; CAS No. 542–75–6). In particular, this document evalu-
ates and summarizes the literature describing the substance’s hazard potential and its 
assessment according to the scientific rationale and framework outlined in CIB 61. In 
meeting this objective, this Skin Notation Profile intends to inform the audience—
mostly occupational health practitioners, researchers, policy- and decision-makers, 
employers, and workers in potentially hazardous workplaces—so that improved risk-
management practices may be developed to better protect workers from the risks of 
skin contact with the chemical of interest.
 
John Howard, M.D. 
Director, National Institute for 
   Occupational Safety and Health 
Centers for Disease Control and Prevention
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Abbreviations
ACGIH American Conference of Governmental Industrial Hygienists 
CIB Current Intelligence Bulletin
cm2 squared centimeter(s)
cm/hr centimeter(s) per hour
1,3-D 1,3-dichloropropene
DEREKTM Deductive Estimation of Risk from Existing Knowledge
DIR skin notation indicating the potential for direct effects to the skin follow- 
   ing contact with a chemical
EC European Commission 
GHS Globally Harmonized System of Classification and Labeling of Chemicals
IARC International Agency for Research on Cancer
(IRR) subnotation of SK: DIR indicating the potential for a chemical to be a 
   skin irritant following exposure to the skin
Kaq coefficient in the watery epidermal layer 
Kp skin permeation coefficient 
Kpol  coefficient in the protein fraction of the stratum corneum
Kpsc  permeation coefficient in the lipid fraction of the stratum corneum 
LD50  dose resulting in 50% mortality in the exposed population
LDLo dermal lethal dose 
log KOW base-10 logarithm of a substance’s octanol–water partition coefficient 
m3 cubic meter(s)
mg milligram(s)
mg/kg milligram(s) per kilogram body weight
mg/m3 milligram(s) per cubic meter
MW molecular weight
NIOSH National Institute for Occupational Safety and Health
NTP National Toxicology Program 
OEL occupational exposure limit
OSHA Occupational Safety and Health Administration
REL recommended exposure limit
RF retention factor 
SEN skin notation indicating the potential for immune-mediated reactions 
   following exposure of the skin
SI ratio ratio of skin dose to inhalation dose
SK skin notation
SW  solubility 
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SYS skin notation indicating the potential for systemic toxicity following 
   exposure of the skin
USEPA United States Environmental Protection Agency 
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Glossary 
Absorption—The transport of a chemical from the outer surface of the skin into both 
the skin and systemic circulation (including penetration, permeation, and resorption). 
Acute exposure—Contact with a chemical that occurs once or for only a short period 
of time. 
Cancer—Any one of a group of diseases that occurs when cells in the body become 
abnormal and grow or multiply out of control. 
Contaminant—A chemical that is (1) unintentionally present within a neat substance 
or mixture at a concentration less than 1.0% or (2) recognized as a potential carcinogen 
and present within a neat substance or mixture at a concentration less than 0.1%. 
Cutaneous (or percutaneous)—Referring to the skin (or through the skin). 
Dermal—Referring to the skin.
Dermal contact—Contact with (touching) the skin. 
Direct effects—Localized, non-immune-mediated adverse health effects on the skin, 
including corrosion, primary irritation, changes in skin pigmentation, and reduction/
disruption of the skin barrier integrity, occurring at or near the point of contact with 
chemicals. 
Immune-mediated responses—Responses mediated by the immune system, including 
allergic responses. 
Sensitization—A specific immune-mediated response that develops following expo-
sure to a chemical, which, upon re-exposure, can lead to allergic contact dermatitis 
(ACD) or other immune-mediated diseases such as asthma, depending on the site and 
route of re-exposure. 
Substance—A chemical. 
Systemic effects—Systemic toxicity associated with skin absorption of chemicals after 
exposure of the skin.
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This Skin Notation Profile presents (1) a 
brief summary of technical data associated 
with skin contact with 1,3-D and (2) the 
rationale behind the hazard-specific skin 
notation (SK) assignment for 1,3-D. The 
SK assignment is based on the scientific 
rationale and logic outlined in the Current 
Intelligence Bulletin (CIB) 61: A Strategy 
for Assigning New NIOSH Skin Notations 
[NIOSH 2009]. The summarized infor-
mation and health hazard assessment are 
limited to an evaluation of the potential 
health effects of dermal exposure to 1,3-D. 
A literature search was conducted through 
July 2010 to identify information on 1,3-D, 
including but not limited to data relating 
to its toxicokinetics, acute toxicity, repeated-
dose systemic toxicity, carcinogenicity, 
biological system/function–specific effects 
(including reproductive and developmental 
effects and immunotoxicity), irritation, and 
sensitization. Information was considered 
from studies of humans, animals, or appro-
priate modeling systems that are relevant to 
assessing the effects of dermal exposure to 
1,3-D. 
1.3 Overview of SK Assignment 
for 1,3-D
1,3-D is potentially capable of causing 
numerous adverse health effects following 
skin contact. A critical review of avail-
able data has resulted in the following 
SK assignment for 1,3-D: SK: SYS-DIR 
(IRR)-SEN. Table 1 provides an overview 
of the critical effects and data used to de-
velop the SK assignment for 1,3-D. The 
following section provides additional de-
tail about the potential health hazards of 
skin contact with 1,3-D and the rationale 
behind the SK assignment. 
1 Introduction 
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1,3-D is a restricted-use pesticide 
applied as a soil fumigant for para-
sitic nematodes; commercially avail-
able formulations of the pesticide are 
a mixture of approximately equal 
proportions of the cis- and trans- 
isomers of 1,3-D [USEPA 1998; 
ATSDR 2008]. In addition, 1,3-D 
is used as an organic solvent and 
chemical intermediate during the 
manufacturing of 3,3-dichloro-1-
propene and other pesticides [NTP 
2005; ATSDR 2008].




2 Systemic Toxicity from Skin 
Exposure (SK: SYS)
No studies were identified regarding the 
absorption of 1,3-D in liquid form after 
dermal exposures in humans or animals. 
The ability of 1,3-D vapor to be readily 
absorbed through the skin has been dem-
onstrated by detection of the metabolite 
cis-1,3-D/mercapturic acid in urine of 
volunteers exposed to cis-1,3-D vapor on 
the forearm skin at a concentration of 86 
milligrams per cubic meter (mg/m3), or 19 
parts per million (ppm), for 45 minutes 
[Kezic et al. 1996]. According to Kezic 
et al. [1996], dermal absorption of 1,3-D 
vapor would account for 2% to 5% of ab-
sorption from inhalation in a whole-body-
exposure scenario. The potential of 1,3-D 
to pose a skin absorption hazard was also 
evaluated, with use of a predictive algo-
rithm for estimating and evaluating the 
health hazards of dermal exposure to sub-
stances [NIOSH 2009]. The evaluation 
method compares an estimated dose accu-
mulated in the body from skin absorption 
and an estimated dose from respiratory 
absorption associated with a reference oc-
cupational exposure limit. On the basis 
of this algorithm, a ratio of the skin dose 
to the inhalation dose (SI ratio) of 2.2 
was calculated for 1,3-D. An SI ratio of 
≥0.1 indicates that a chemical is capable 
of producing systemic toxicity from skin 
exposure [NIOSH 2009]. Additional in-
formation on the SI ratio and the variables 
used in its calculation are included in the 
appendix. 
Although no dermal lethal dose (LDLo) 
has been established for humans, the fol-
lowing values for dermal LD50 (the dose 
resulting in 50% mortality in the exposed 
population) have been reported for com-
mercial pesticide formulations containing 
1,3-D: a range of 333 milligrams per ki-
logram body weight (mg/kg) to 504 mg/
kg for rabbits [Dow Chemical USA 1975, 
Dow Chemical Company 1987a] and a 
value of 1200 mg/kg for rats [Dow Chemi-
cal Company 1986]. The clinical signs of 
toxicity reported in these studies included 
incoordination (ataxia), lethargy, and sali-
vation. Because the reported LD50 values 
for rats and rabbits are below the critical 
LD50 value of 2000 mg/kg that identifies 
substances with potential for acute dermal 
toxicity [NIOSH 2009], 1,3-D is consid-
ered systemically available and can be neu-
rotoxic following acute dermal exposure.
No epidemiological studies were identi-
fied that evaluated the potential of 1,3-D 
to cause systemic effects following dermal 
exposure. Additionally, no information 
was identified about the potential system-
ic effects in animals following repeat-dose 
(21-day or 28-day), subchronic (90-day), 
or chronic (at least 12-month) dermal 
exposure to any of the isomers of 1,3-D. 
No standard toxicity or specialty studies 
of biological system or function–specific 
effects (including reproductive and de-
velopmental effects and immunotoxicity) 
following dermal exposure to dichloro-
propene were identified. In addition, no 
studies were located regarding cancer in 
humans after dermal exposure to 1,3-D or 
Table 1. Summary of the SK Assignment for 1,3-D
Skin notation Critical effect Data available
SK: SYS Neurotoxicity Limited human data; sufficient animal data
SK: DIR (IRR) Skin irritation Sufficient animal data
SK: SEN Skin allergy Limited human data; sufficient animal data
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any other dichloropropene isomers. Table 
2 summarizes carcinogenic designations 
of multiple governmental and nongovern-
mental organizations for 1,3-D.  
The limited dermal toxicokinetic data on 
humans [Kezic et al. 1996]* demonstrate 
that 1,3-D vapor has the potential to be 
absorbed through the skin. The results 
from acute dermal toxicity studies of ani-
mals [Dow Chemical USA 1975, Dow 
Chemical Company 1986, 1987a] are 
sufficient to demonstrate that 1,3-D is 
systemically available and can be neuro-
toxic. Therefore, on the basis of the data 
for this assessment, 1,3-D is assigned the 
SK: SYS notation. 
3  Direct Effects on Skin 
(SK: DIR)
A literature search revealed no data on 
corrosivity of 1,3-D; no in vitro tests for 
either corrosivity (with use of human or 
*References in bold text indicate studies that serve 
as the basis of the SK assignments.
animal skin models) or skin integrity (with 
use of cadaver skin); and no tests in hu-
mans to evaluate the potential of 1,3-D 
to be a skin irritant. However, a primary 
skin irritation test [Dow 1987b] indicated 
that 1,3-D caused slight to moderate ery-
thema and edema when 0.5 milliliter of 
the undiluted substance was applied under 
occlusion to the skin of rabbits for 4 hours. 
Skin irritation was also noted in acute der-
mal toxicity studies in the rat and rabbit 
[Dow Chemical USA 1975, Dow Chemi-
cal Company 1986, 1987b]. The structure 
activity relationship model, Deductive Es-
timation of Risk from Existing Knowledge 
(DEREKTM) for Windows, predicted 1,3-
D to be negative for skin irritation.
Van Duuren et al. [1979] conducted an 
initiation-promotion study of cis-1,3-D 
dermal exposure in mice. The authors con-
cluded that 1,3-D was not a tumor initia-
tor and did not induce skin tumors in mice 
(1) after a single topical application of 122 
milligrams (mg), followed by repeated ap-
plications of the tumor promoter phorbol 
myristate acetate, for at least 428 days or 
(2) after topical application of 122 mg 
three times weekly for at least 440 days.
Table 2. Summary of the carcinogenic designations* for 1,3-D by numerous 
governmental and nongovernmental organizations
Organization Carcinogenic designation 
NIOSH [2005] Potential occupational carcinogen 
NTP [2005] Reasonably anticipated to be a human carcinogen
USEPA [2010] Group B2: Probable human carcinogen (based on sufficient evidence of carci-
nogenicity in animals)
IARC [1999] Group 2B: Possibly carcinogenic to humans
EC [2010] No designation
ACGIH [2005] Group A3: Confirmed animal carcinogen with unknown relevance to humans
Abbreviations: ACGIH=American Conference of Governmental Industrial Hygienists; EC=European Commission, Joint Research, 
Institute for Health and Consumer Protection; IARC=International Agency for Research on Cancer; NIOSH=National Institute 
for Occupational Safety and Health; NTP=National Toxicology Program; USEPA=United States Environmental Protection 
Agency.
*The listed cancer designations were based on data from nondermal (such as oral or inhalation) exposure rather than dermal ex-
posure. 




Data from primary skin irritation tests 
and acute dermal toxicity studies in ani-
mals [Dow Chemical USA 1975, Dow 
Chemical Company 1986, 1987b] are suf-
ficient to demonstrate that 1,3-D causes 
skin irritation. Therefore, on the basis of 
the data for this assessment, 1,3-D is as-
signed the SK: DIR (IRR) notation. 
4  Immune-mediated 
Responses (SK: SEN)
The potential of 1,3-D to cause skin sen-
sitization following repeated or prolonged 
exposure has been demonstrated in case 
reports and animal studies. The results of 
diagnostic patch tests suggest that 1,3-D 
has the potential to cause skin sensitiza-
tion in humans [van Joost and de Jong 
1988; Bousema et al. 1991; Vozza et al. 
1996; Corazza et al. 2003]. Delayed-type 
hypersensitivity was noted in four work-
ers involved in the production or use of 
pesticides containing 1,3-D.  The workers 
developed dermatitis with erythema and 
itching vesicles 3 weeks after exposure 
[van Joost and de Jong 1988; Bousema 
et al. 1991; Vozza et al. 1996; Corazza 
et al. 2003]. Skin allergic reactions have 
also been demonstrated in 4 of 10 [Dow 
Chemical USA 1983] and 9 of 10 [Dow 
Chemical Company 1987c] guinea pigs in 
maximization tests. DEREKTM predicted 
1,3-D to be a plausible skin sensitizer.
Diagnostic patch tests in humans [van Joost 
and de Jong 1988; Bousema et al. 1991; 
Vozza et al. 1996; Corazza et al. 2003] 
have provided limited data indicating that 
1,3-D is a skin sensitizer. However, results 
from guinea pig maximization tests [Dow 
Chemical USA 1983, Dow Chemical 
Company 1987c] have provided sufficient 
evidence that 1,3-D elicits allergic contact 
dermatitis in animals. Therefore, on the 
basis of the data for this assessment, 1,3-D 
is assigned the SK: SEN notation. 
5  Summary
Data from a dermal toxicokinetic study 
using human volunteers demonstrate ab-
sorption of 1,3-D vapor through the skin 
[Kezic et al. 1996]. Acute dermal toxicity 
studies [Dow Chemical USA 1975, Dow 
Chemical Company 1986, 1987a] have 
provided sufficient evidence that 1,3-D is 
absorbed through the skin and can cause 
systemic effects such as neurotoxicity. 
Data from animal studies are sufficient to 
demonstrate that 1,3-D has the potential 
to cause skin irritation [Dow Chemical 
USA 1975, Dow Chemical Company 
1986, 1987b]. Whereas the results of di-
agnostic patch tests suggest that 1,3-D has 
the potential to cause skin sensitization 
in humans [Van Joost and de Jong 1988; 
Bousema et al. 1991; Vozza et al. 1996; 
Corazza et al. 2003], results of guinea pig 
maximization tests [Dow Chemical USA 
1983, Dow Chemical Company 1987c] 
provide sufficient evidence that 1,3-D 
elicits allergic contact dermatitis in hu-
mans and animals. Therefore, on the basis 
of these assessments, 1,3-D is assigned a 
composite skin notation of SK: SYS-DIR 
(IRR)-SEN. 
Table 3 summarizes the skin hazard des-
ignations for 1,3-D previously issued by 
NIOSH and other organizations. The equi- 
valent dermal designations for 1,3-D, ac-
cording to the Globally Harmonized System 
of Classification and Labeling of Chemi-
cals (GHS), are Acute Toxicity Category 4 
(Hazard statement: Harmful in contact with 
the skin), Skin Irritation Category 2 (Hazard 
statement: Causes skin irritation), and Skin 
Sensitization Category 1 (Hazard statement: 
May cause an allergic skin reaction) [Euro-
pean Parliament 2008].  




Note: Asterisks (*) denote sources cited 
in text; daggers (†) denote additional re-
sources.
*ACGIH (American Conference of Governmen-
tal Industrial Hygienists) [2005]. 1,3-Dichlo-
ropropene. In: Documentation of threshold 
limit values and biological exposure indices. 7th 
Ed., Vol. 1. Cincinnati, OH: American Confer-
ence of Governmental Industrial Hygienists.
*ATSDR (Agency for Toxic Substances and Dis-
ease Registry) [2008]. Toxicological profile for 
dichloropropenes. Atlanta, GA: U.S. Depart-
ment of Health and Human Services, Public 
Health Service, ATSDR [http://www.atsdr.cdc.
gov/toxprofiles/tp40.pdf ]. Accessed 12–02–09.
*Bousema MT, Wiemer GR, van Joost T [1991]. 
A classic case of sensitization to DD-95. Con-
tact Dermatitis 24(2):132–133. 
*Corazza M, Zinna G, Virgili A [2003]. Allergic 
contact dermatitis due to 1,3-dichloropropene 
soil fumigant. Contact Dermatitis 48(6):341–
342. 
*Dow Chemical Company [1986]. Telone II® 
(1,3-dichloropropene) OECD 402: acute der-
mal toxicity test in the rat. On file with the 
U.S. Environmental Protection Agency under 
TSCA Section 8D. OTS #0515824. Document 
#86-870002300.  
*Dow Chemical Company [1987a]. Telone II® 
(1,3-dichloropropene) soil fumigant: acute 
dermal toxicity study in New Zealand white 
rabbits. Midland, MI: Dow Chemical Com-
pany. On file with the U.S. Environmental 
Protection Agency under TSCA Section 8D. 
OTS #0515820. Document 86-870002296.  
*Dow Chemical Company [1987b]. Telone II® 
soil fumigant: primary dermal irritation study 
in New Zealand white rabbits. Midland, MI: 
Dow Chemical Company. On file with the 
U.S. Environmental Protection Agency under 
TSCA Section 8D. OTS #0517081. Document 
#86-870002291.
*Dow Chemical Company [1987c]. Telone II® 
(1,3-dichloropropene) soil fumigant: dermal 
sensitization potential in the Hartley albino 
guinea pig. Midland, MI: Dow Chemical Com-
pany. On file with the U.S. Environmental Pro-
tection Agency under TSCA Section 8D. OTS 
#0515819. Document #86-870002295.  
†Dow Chemical Company [1988a]. C-17® soil 
fungicide and nematicide: dermal sensitiza-
tion potential in the Hartley albino guinea 
pig. Midland, MI: Dow Chemical Company. 
Dow Report Identification Number D002749. 
On file with the U.S. Environmental Protec-
tion Agency under TSCA Section 8D. OTS 
#0516507.  Document #86-880000357.  
†Dow Chemical Company [1988b]. C-17® soil 
fungicide and nematicide: primary dermal ir-
ritation study in New Zealand white rabbits. 
Midland, MI: Dow Chemical Company. Dow 
Report Identification Number D002750. On file 
with the U.S. Environmental Protection Agency 
under TSCA Section 8D. OTS #0516580. Doc-
ument #86-890000001.
*Dow Chemical USA [1975]. Acute toxicological 
properties of experimental nematicide formu-
lation M-3993 containing 1,3-dichloropropene. 
Midland, MI: Dow Chemical USA. On file with 
the U.S. Environmental Protection Agency under 
Table 3. Summary of the previously issued skin hazard designations for 1,3-D
Organization Skin hazard designation 
NIOSH [2005] [skin]: Potential for dermal absorption; prevent skin contact
OSHA None assigned
ACGIH [2005] [skin]: Based on evidence of skin penetration of 1,3-D, with subsequent 
mortality, in treated rabbits
EC [2010] R21: Harmful if in contact with skin
R38: Irritating to skin
R43: May cause sensitization by skin contact
Abbreviations: ACGIH = American Conference of Governmental Industrial Hygienists; EC = European Commission, Joint 
Research, Institute for Health and Consumer Protection; NIOSH = National Institute for Occupational Safety and Health; 
OSHA = Occupational Safety and Health Administration.




TSCA Section 8D. OTS #0515857. Document 
#86-870002333.
*Dow Chemical USA [1983]. Telone II®: skin 
sensitization potential in the guinea pig. Mid-
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Appendix: Calculation of the SI atio for 1,3-D
The algorithm is flexible in the data re-
quirement and can operate entirely on the 
basis of the physicochemical properties 
of a substance and the relevant exposure 
parameters. Thus, the algorithm is inde-
pendent of the need for biologic data. Al-
ternatively, it can function with both the 
physicochemical properties and the ex-
perimentally determined permeation co-
efficient when such data are available and 
appropriate for use.
The first step in the evaluation is to deter-
mine the Kp for the substance to describe 
the transdermal penetration rate of the 
substance [NIOSH 2009]. The Kp, which 
represents the overall diffusion of the sub-
stance through the stratum corneum and 
into the blood capillaries of the dermis, is 
estimated from the compound’s molecular 
weight (MW) and base-10 logarithm of 
its octanol–water partition coefficient (log 
KOW). In this example, Kp is determined 
for a substance with use of Equation 1. A 
self-consistent set of units must be used, 
such as centimeters per hour (cm/hr), out-
lined in Table A1. Other model-based es-
timates of Kp may also be used [NIOSH 
2009].
Equation 1: Calculation of skin permeation 
coefficient (Kp)
This appendix presents an overview of the 
SI ratio and a summary of the calculation 
of the SI ratio for 1,3-D. Although the SI 
ratio is considered in the determination of 
a substance’s hazard potential following 
skin contact, it is intended only to serve as 
supportive data during the assignment of 
the NIOSH SK. An in-depth discussion 
on the rationale and calculation of the SI 
ratio can be found in Appendix B of the 
Current Intelligence Bulletin (CIB) 61: A 
Strategy for Assigning New NIOSH Skin 
Notations [NIOSH 2009]. 
Overview 
The SI ratio is a predictive algorithm for 
estimating and evaluating the health haz-
ards of skin exposure to substances. The al-
gorithm is designed to evaluate the poten-
tial for a substance to penetrate the skin 
and induce systemic toxicity [NIOSH 
2009]. The goals for incorporating this 
algorithm into the proposed strategy for 
assigning SYS notation are as follows:
1. Provide an alternative method to eval-
uate substances for which no clinical 
reports or animal toxicity studies exist 
or for which empirical data are insuf-
ficient to determine systemic effects.
2. Use the algorithm evaluation results to 
determine whether a substance poses a 
skin absorption hazard and should be 
labeled with the SYS notation.
The algorithm evaluation includes three 
steps: (1) determining a skin permeation 
coefficient (Kp) for the substance of in-
terest, (2) estimating substance uptake by 
the skin and respiratory absorption routes, 
and (3) evaluating whether the substance 
poses a skin exposure hazard.
where Kpsc is the permeation coefficient in 
the lipid fraction of the stratum corneum, 
Kpol is the coefficient in the protein frac-
tion of the stratum corneum, and Kaq is the 




coefficient in the watery epidermal layer. 
These components are individually esti-
mated by
log Kpsc = −1.326 + 0.6097 × log KOW − 
0.1786 × MW 0.5
Kpol = 0.0001519 × MW−0.5
Kaq = 2.5 × MW−0.5
The second step is to calculate the biologic 
mass uptake of the substance from skin 
absorption (skin dose) and inhalation (in-
halation dose) during the same period of 
exposure. The skin dose is calculated as a 
mathematical product of the Kp, the water 
solubility (SW) of the substance, the ex-
posed skin surface area, and the duration 
Table A1. Summary of data used to calculate the SI ratio for 1,3-D  
Variables used in calculation Units Value 
Skin permeation coefficient
Permeation coefficient of stratum corneum lipid path(Kpsc) cm/hr 0.01087
Permeation coefficient of the protein fraction of the stratum 
corneum (Kpol)
cm/hr 1.4497 × 10-5
Permeation coefficient of the watery epidermal layer (Kaq) cm/hr 0.23732
Molecular weight (MW)* amu 110.97
Base-10 logarithm of its octanol–water partition coefficient (Log 
KOW)*
None 2.04
Calculated skin permeation coefficient (Kp) cm/hr 0.01041
Skin dose
Water solubility (SW)* mg/cm3 2.8
Calculated skin permeation coefficient (Kp) cm/hr 0.01041
Estimated skin surface area (palms of hand) cm2 360
Exposure time hr 8
Calculated skin dose mg 83.95
Inhalation Dose
Occupational exposure limit (OEL)† mg/m3 5
Inhalation volume m3 10
Retention factor (RF) None 0.75
Inhalation dose mg 37.5
Skin dose–to–inhalation dose (SI) ratio None 2.24
*Variables identified from SRC [2009].
†The OEL used in calculation of the SI ratio for 1,3-D was the NIOSH recommended exposure limit (REL) [NIOSH 2005].
of exposure. Its units are milligrams (mg). 
Assume that the skin exposure continues 
for 8 hours to unprotected skin on the 
palms of both hands (a surface area of 360 
squared centimeters [cm2]). 
Equation 2: Determination of Skin Dose
Skin dose = Kp × SW × Exposed skin sur-
face area × Exposure time
= Kp(cm/hr) × SW (mg/cm3) × 
360 cm2 × 8 hr
The inhalation dose (in mg) is derived on 
the basis of the occupational exposure 
limit (OEL) of the substance—if the OEL 
is developed to prevent the occurrence of 
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systemic effects rather than sensory/irri-
tant effects or direct effects on the respira-
tory tract. Assume a continuous exposure 
of 8 hours, an inhalation volume of 10 
cubic meters (m3) inhaled air in 8 hours, 
and a factor of 75% for retention of the 
airborne substance in the lungs during 
respiration (retention factor, or RF).
Equation 3: Determination of Inhalation Dose
Inhalation dose = OEL × Inhalation 
volume × RF
= OEL (mg/m3) × 10 m3 
× 0.75
The final step is to compare the calculated 
skin and inhalation doses and to present 
the result as a ratio of skin dose to inhala-
tion dose (the SI ratio). This ratio quan-
titatively indicates (1) the significance of 
dermal absorption as a route of occupa-
tional exposure to the substance and (2) 
the contribution of dermal uptake to sys-
temic toxicity. If a substance has an SI ra-
tio greater than or equal to 0.1, it is con-
sidered a skin absorption hazard.
Calculation 
Table A1 summarizes the data applied in 
the previously described equations to de-
termine the SI ratio for 1,3-D. The cal-
culated SI ratio was 2.24. On the basis of 
these results, 1,3-D is predicted to repre-
sent a skin absorption hazard. 
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